Abstract:
Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
Abstract:
The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
Abstract:
The invention is concerned with crystalline forms or amorphous forms of a pyrrolidine- 3,4-dicarboxamide derivative, which is useful as an active ingredient of medicaments for the diseases which can be treated by the coagulation factor Xa inhibitors.
Abstract:
The invention is concerned with novel heteroarylacetamides of formula (I) R d -C(O)-N(R e )-R c -CH 2 -C(O)-N(R a )(R b ), wherein R a to R e are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
Abstract translation:本发明涉及式(I)的新型杂芳基乙酰胺R 2 -C(O)-N(R e) - R c - CH 2 -C(O)-N(R a)a(R b)b)其中R a a至 R e如在说明书和权利要求书中所定义的,以及其生理上可接受的盐。 这些化合物抑制凝血因子Xa,并且可以用作药物。
Abstract:
The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, R C , D and E are as defined in the description and in the claims, as well 5as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
Abstract:
The invention is concerned with novel carbocyclyl fused cyclic amines of formula (I) wherein A, X 1 to X 3 , Y 1 to Y 3 , Z, R 1 , R 2 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
Abstract:
The invention is concerned with novel cyclic amines of formula (I) wherein X 1 to X 3 , Y 1 to Y 3 , R 1' , R 1'' and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
Abstract:
The present invention relates to compound of formula (I) wherein R , R , R , R , R , R , R , and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases, which are associated with the modulation of CB1 receptors.
Abstract:
The present invention provides compounds of formula I or II: (I) wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.